摘要
目的探讨哌罗匹隆治疗精神分裂症的效果。方法采用随机数字表法将符合《中国精神障碍分类与诊断标准（第3版）》（CCMD-3）的113例精神分裂症患者分为两组,分别给予哌罗匹隆与舒必利治疗。哌罗匹隆初始剂量8 mg/d,分2次给药,2周内逐渐增至16~48mg/d,舒必利初始剂量200mg/d,分2次给药,2周内逐渐增至600~900mg/d。疗程为8周。采用阳性与阴性症状量表（PANSS）评定疗效,副反应量表（TESS）、实验室检查评定不良副反应。结果经8周治疗,两组PANSS总评分均较治疗前低（P均〈0.01）。哌罗匹隆组与舒必利组总有效率分别为77.19%和73.21%,差异无统计学意义（P〉0.05）,但哌罗匹隆组较舒必利组对阳性症状起效更好更快（P〈0.05）。结论哌罗匹隆对精神分裂症的疗效与舒必利相当。
Objective To study the effectiveness of schizophrenia patients treated with perospirone. Methods 113 patients of schizophrenia were randomly assigned to perospirone group and sulpiride group. Period of treatment was 8 weeks. The efficacy were as-sessed by Positive and Negative Syndrome Scale（PANSS）,adverse side effect were evaluated with Treatment Emergent Symptom Scale （TESS）. Results After 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline（P 〈0. 01）. The efficacy rates of the perospirone group and sulpiride group were 77. 19% and 73. 21% respectively. No significant differ-ence was found between two groups（P ﹥ 0. 05）. Perospirone group is more effective in the treatment of positive symptoms than sulpiride group（P 〈 0. 05）. Conclusion Perospirone is as effective as sulpiride for the treatment of schizophrenia patients.
出处
《四川精神卫生》
2015年第2期141-143,共3页
Sichuan Mental Health
